Literature DB >> 10331746

Involvement of mutations in the DPC4 promoter in endometrial carcinoma development.

Y Zhou1, H Kato, D Shan, R Minami, S Kitazawa, T Matsuda, T Arima, J C Barrett, N Wake.   

Abstract

To define the target of chromosome 18q loss of heterozygosity, which is prevalent in endometrial carcinomas, we made a deletion map from 64 tumors. Loss of heterozygosity on 18q was found in 20 tumors. Among these, 14 tumors carried deletions at the 18q21.1 region, where the DPC4 gene is located. DPC4 transcription was disturbed in all six of the tumors with deletions at 18q21.1 examined, which sharply contrasted with the positive transcription in 12 tumors that retained heterozygosity at the 18q21.1 region. However, in the 14 tumors with the 18q21.1 deletions, the remaining allele had the wild-type sequence of the DPC4 coding region instead of somatic mutations in the DPC4 coding region. We found a one- and two-base substitutions in the DPC4 promoter in two of the six tumors that showed disturbed DPC4 transcription. Chloramphenicol acetyltransferase assays clearly demonstrated that the mutant promoters had the potential to suppress or silence DPC4 transcription, implicating the DPC4 gene in endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331746     DOI: 10.1002/(sici)1098-2744(199905)25:1<64::aid-mc8>3.0.co;2-z

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  8 in total

1.  Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.

Authors:  A Maitra; K Molberg; J Albores-Saavedra; G Lindberg
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Authors:  Shih-Chang Chuang; King-Teh Lee; Kun-Bow Tsai; Pai-Ching Sheen; Eishi Nagai; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

4.  Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation.

Authors:  B A Onwuegbusi; A Aitchison; S-F Chin; T Kranjac; I Mills; Y Huang; P Lao-Sirieix; C Caldas; R C Fitzgerald
Journal:  Gut       Date:  2005-12-20       Impact factor: 23.059

5.  Discovery of SMAD4 promoters, transcription factor binding sites and deletions in juvenile polyposis patients.

Authors:  Daniel Calva; Fadi S Dahdaleh; George Woodfield; Ronald J Weigel; Jennifer C Carr; Sathivel Chinnathambi; James R Howe
Journal:  Nucleic Acids Res       Date:  2011-03-17       Impact factor: 16.971

6.  No SMAD4 hypermethylation in colorectal cancer.

Authors:  S Roth; P Laiho; R Salovaara; V Launonen; L A Aaltonen
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

7.  Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.

Authors:  Xu Jia; Chandrakumar Shanmugam; Ravi K Paluri; Nirag C Jhala; Michael P Behring; Venkat R Katkoori; Shajan P Sugandha; Sejong Bae; Temesgen Samuel; Upender Manne
Journal:  Oncotarget       Date:  2017-03-21

8.  Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats.

Authors:  Victoria L Herrera; Lorenz R Ponce; Nelson Ruiz-Opazo
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.